| # | Drug | Count |
|---|---|---|
| 0 | CISPLATIN | 68 |
| 1 | OMEPRAZOLE MAGNESIUM | 66 |
| 2 | BISOPROLOL FUMARATE | 61 |
| 3 | OMEPRAZOLE | 59 |
| 4 | PREDNISOLONE | 57 |
| 5 | PREDNISOLONE ORAL | 57 |
| 6 | PREDNISOLONE ORAL SOLUTION | 57 |
| 7 | TACROLIMUS | 48 |
| 8 | FUROSEMIDE | 47 |
| 9 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 42 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PORFIMER SODIUM | 7 | 0.0205 |
| 1 | SENNOSIDES A AND B | 27 | 0.0164 |
| 2 | ALLOPURINOL SODIUM | 9 | 0.0160 |
| 3 | FLOXURIDINE | 2 | 0.0116 |
| 4 | GLUCAGON | 31 | 0.0073 |
| 5 | HYDROCHLORIC ACID | 1 | 0.0045 |
| 6 | TISLELIZUMAB-JSGR | 1 | 0.0045 |
| 7 | DIBASIC SODIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE AND MONOBASIC SODIUM PHOSPHATE | 1 | 0.0030 |
| 8 | REPAGLINIDE | 20 | 0.0026 |
| 9 | EPLERENONE | 34 | 0.0026 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 111 |
| 1 | Platinum-based Drug [EPC] | 109 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 90 |
| 3 | Proton Pump Inhibitor [EPC] | 78 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 62 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 51 |
| 6 | Loop Diuretic [EPC] | 48 |
| 7 | Kinase Inhibitor [EPC] | 47 |
| 8 | Microtubule Inhibitor [EPC] | 45 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 40 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antihypoglycemic Agent [EPC] | 31 | 0.0072 |
| 1 | Glinide [EPC] | 20 | 0.0022 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 7 | 0.0011 |
| 3 | Surfactant [EPC] | 1 | 0.0009 |
| 4 | Vesicular Monoamine Transporter 2 Inhibitor [EPC] | 1 | 0.0008 |
| 5 | Macrolide Antimicrobial [EPC] | 37 | 0.0007 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 51 | 0.0005 |
| 7 | Tetracycline-class Drug [EPC] | 35 | 0.0005 |
| 8 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 9 | Topoisomerase Inhibitor [EPC] | 31 | 0.0004 |